Clinical trials: Myeloid
Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies.
- Conditions
- Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01696461
- Testing
- Plerixafor
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers…
- Trial name
- THINK (NCT03018405)
- Testing
- NKR-2 cells
- Where
- 5 sites in United States, Belgium
- Volunteers
- 146 people
- Sponsor
- Celyad Oncology SA
Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who…
- Trial name
- NCT06915766
- Testing
- Bezuclastinib
- Where
- 23 sites in United States
- Sponsor
- Cogent Biosciences, Inc.
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
Chronic Myeloid Leukemia, Accelerated Phase CML
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI)…
- Trial name
- NCT06453902
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Acute Lymphoblastic Leukemias, Acute Myelocytic Leukemia
Stem Cell Transplantation for Patients With Hematologic Malignancies
Childhood leukemias which cannot be cured by chemotherapy alone may be effectively treated by allogeneic bone marrow transplantation.
- Conditions
- Acute Lymphoblastic Leukemias, Acute Myelocytic Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT00152139
- Testing
- Allogeneic Stem Cell Transplantation, Chemotherapy and antibodies
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
RATIONALE: Studying a diagnostic biomarker test in blood samples from patients who have undergone a donor stem cell transplant for cancer may help doctors plan treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00813501
- Testing
- immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure.
- Conditions
- Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma
- Trial name
- FluBuBe (NCT04942730)
- Testing
- Fludarabine, Bendamustine Hydrochloride, Busulfan
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Chronic Myeloid Leukemia
The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Research Hypothesis: Treatment with dasatinib 100 mg QD is superior to imatinib 600 mg QD in terms of complete cytogenetic response (CCyR) in chronic phase (CP) Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia…
- Trial name
- NCT00854841
- Testing
- Dasatinib and Imatinib
- Sponsor
- Pusan National University Hospital
Cancer Survivor, Cognitive/Functional Effects
Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction
RATIONALE: An educational and skills training program for the parent of a childhood cancer survivor with neurobehavioral dysfunction may help improve the child's school performance, thinking ability, and behavior.
- Conditions
- Cancer Survivor, Cognitive/Functional Effects, Leukemia, Long-term Effects Secondary to Cancer Therapy in Children
- Trial name
- NCT00713505
- Testing
- educational intervention, psychosocial assessment and care
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
This study is being done to determine if treatment with azacitidine and venetoclax is effective treatment for elderly patients with acute myeloid leukemia (AML) who have not received previous treatment.
- Trial name
- NCT03466294
- Testing
- Azacitidine and Venetoclax
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Colorado, Denver
Leukemia
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth…
- Trial name
- NCT00268229
- Testing
- cytarabine, daunorubicin hydrochloride, imatinib mesylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The Cleveland Clinic
AML, Adult
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
All patients receiving induction, consolidation and salvage chemotherapy, and autologous or allogeneic stem cell transplantation according to a strategy defined in the GIMEMA AML1310 protocol will be prospectively monitored for…
- Trial name
- AML1411 (NCT01570465)
- Testing
- Observation
- Where
- 46 sites in Italy
- Volunteers
- 144 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia
Late Chronic Phase Chronic Myelogenous Leukemia
Objectives: Primary endpoints: To achieve low levels of Polymerase Chain Reaction (PCR) ratios of B-cell antigen receptor (Bcr-Abl)/Bcr (molecular CR) in a significant proportion of patients after 12 months of higher doses (800…
- Trial name
- NCT01092741
- Testing
- Gleevec
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignancy, Cancer
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.
- Conditions
- Advanced Malignancy, Cancer, Oncology, Oncology Patients
- Trial name
- NCT02016729
- Testing
- AMG 232, Trametinib
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Kartos Therapeutics, Inc.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
- Trial name
- NCT02492737
- Testing
- AG881
- Where
- 6 sites in United States, France
- Volunteers
- 46 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Leukemia, Lymphoma
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00002681
- Testing
- aldesleukin, daclizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roger Williams Medical Center
Myeloma, Lymphoma
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
A prospective study in which hematological oncology patients who were vaccinated against RSV will undergo a blood test to assess their immune response to the vaccine.
- Conditions
- Myeloma, Lymphoma, CLL, Myelodysplastic Syndrome
- Trial name
- NCT06944119
- Where
- Israel
- Volunteers
- 250 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Chronic Myelomonocytic Leukemia
The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
The purpose of this study is to evaluate the level of a specific protein (PTEN) in the cancer cells of chronic myelomonocytic leukemia (CMML) patients.
- Trial name
- NCT01010256
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.